Dexamethasone Acetate

Catalog No.S3124 Batch:S312401

Print

Technical Data

Formula

C24H31FO6

Molecular Weight 434.5 CAS No. 1177-87-3
Solubility (25°C)* In vitro DMSO 87 mg/mL (200.23 mM)
Ethanol 20 mg/mL (46.02 mM)
Water Insoluble
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description Dexamethasone (NSC 39471,Dexamethasone 21-acetate) is a potent synthetic member of the glucocorticoid class of steroid drugs, and an interleukin receptor modulator that has anti-inflammatory and immunosuppressant effects.
Targets
interleukin receptor [1]
In vitro

Dexamethasone inhibits COX-2 mRNA expression induced by IL-1 in human articular chondrocytes. [1] Dexamethasone suppresses the cyclooxygenase-2 induction by tumor necrosis factor α (TNFα) with an IC50 of 1 nM in MC3T3-E1 cells. Dexamethasone binds to the glucocorticoid receptor and then to the glucocorticoid response element. [2]Dexamethasone (10 μM) induces osteoblastic differentiation of rat bone marrow stromal cell cultures with elevated mRNA expression of alkaline phosphatase osteopontin, bone sialoprotein, and osteocalcin. [3] Dexamethasone (5 μM) treatment decreases proliferation of adult hippocampal neural progenitor cells and SRE-driven gene expression. [5]

In vivo

Dexamethasone (2 mg/kg) reduces the number of the BrdU-labeled hepatocytes by 80% in male Fischer F344 rats. Dexamethasone (2 mg/kg) pretreatment suppresses the expression of both TNF and IL-6 after partial hepatectomy and significantly reduces the proliferative response of the hepatocytes in male Fischer F344 rats. Dexamethasone also severely diminishes the induction and expansion of oval cells induced by the 2-acetylaminofluorene/partial hepatectomy (AAF/PH) protocol but does not have any effect on the proliferation of the bile duct cells stimulated by bile duct ligation. [4] Dexamethasone (100 μg/kg) produces a significant decrease 59.2% of BrdU(+) hippocampal progenitor cells in Sprague–Dawley rats. Dexamethasone (100 μg/kg) decreases ERK activation in granule cell layer in Sprague–Dawley rats. [5]

Protocol (from reference)

Animal Study:

[5]

  • Animal Models

    Sprague-Dawley rats

  • Dosages

    100 μg/kg

  • Administration

    Intraperitoneal injection

Customer Product Validation

Data from [Oncogene, 2013, 32, 1316-29]

Data from [Oncogene, 2013, 32, 1316-29]

Selleck's Dexamethasone Acetate has been cited by 35 publications

In vitro protocol for the optimal induction of inflammation in human monocyte cell lines [ STAR Protoc, 2023, 4(2):102342] PubMed: 37300827
BMS794833 inhibits macrophage efferocytosis by directly binding to MERTK and inhibiting its activity [ Exp Mol Med, 2022, 54(9):1450-1460] PubMed: 36056187
Topical phenylbutyrate antagonizes NF-κB signaling and resolves corneal inflammation [ iScience, 2022, 25(12):105682] PubMed: 36536680
Enhanced Differentiation Capacity and Transplantation Efficacy of Insulin-Producing Cell Clusters from Human iPSCs Using Permeable Nanofibrous Microwell-Arrayed Membrane for Diabetes Treatment [ Pharmaceutics, 2022, 14(2)400] PubMed: 35214135
Dexamethasone Sensitizes Acute Monocytic Leukemia Cells to Ara-C by Upregulating FKBP51 [ Front Oncol, 2022, 12:888695] PubMed: 35860568
Ponatinib sensitizes myeloma cells to MEK inhibition in the high-risk VQ model [ Sci Rep, 2022, 12(1):10616] PubMed: 35739276
PON2 blockade overcomes dexamethasone resistance in acute lymphoblastic leukemia [ Hematology, 2022, 27(1):32-42] PubMed: 34957927
CHEK1 and circCHEK1_246aa evoke chromosomal instability and induce bone lesion formation in multiple myeloma [ Mol Cancer, 2021, 20(1):84] PubMed: 34090465
Genetic in situ engineering of myeloid regulatory cells controls inflammation in autoimmunity [ J Control Release, 2021, S0168-3659(21)00446-6] PubMed: 34437913
A universal gene correction approach for FKRP-associated dystroglycanopathies to enable autologous cell therapy [ Cell Rep, 2021, 36(2):109360] PubMed: 34260922

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.